Comera Life Sciences announced that it will collaborate with Intas Pharmaceuticals to develop a new generation of biologic medicines.
Woburn, Massachusetts-based Comera will develop a differentiated formulation of an Intas product using its SQore formulation platform, while Ahmedabad, India-based Intas will provide research funding with the option to acquire global rights to the formulation through an exclusive license with responsibility for subsequent development and commercialization.
Comera designed its reformulation platform to replace hours-long infusion treatments with one-shot self-injections, creating an easier, more efficient method of receiving treatment for patients.
“This collaboration is the latest step in our long-term partnership strategy to leverage our SQore platform and transition from preclinical, early-stage assets to late-stage, marketed products,” Comera Chair and CEO Jeff Hackman said in a news release. “We look forward to working with Intas and developing a differentiated formulation that will make it easier for patients to use and increase healthcare savings.”
